Cited by 172Histone Deacetylase Inhibitors ResearchEpigenetics and DNA MethylationTreatment of Major Depression

The DOI matches its Crossref record; 83 of the 85 references it cites were found in a registry or an index.

Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders

Grayson, Dennis R., Kundakovic, Marija, Sharma, Rajiv P.·2010·Molecular Pharmacology

Open this paper in CoChat — free account

Abstract

In recent years, it has become widely recognized that a comprehensive understanding of chromatin biology is necessary to better appreciate its role in a wide range of diseases. The histone code has developed as a new layer of our appreciation of transcription factor-based mechanisms of gene expression. Although epigenetic regulation refers to a host of chromatin modifications that occur at the level of DNA, histones, and histone-associated proteins, how this regulation is orchestrated is still incompletely understood. Of those processes that comprise the epigenetic regulatory machinery, DNA methylation and histone acetylation/deacetylation have been the most thoroughly studied. Compounds that act as inhibitors of DNA methyltransferases or histone deacetylases (HDACs) activate a variety of intracellular signaling pathways that ultimately affect the coordinated expression of multiple genes. The altered patterns of mRNA and protein expression collectively converge on pathways linked to apoptosis and cell cycle arrest, among others. This has prompted a widespread search for epigenetic inhibitors that could be used as chemotherapeutic agents, and several are undergoing clinical evaluation. More recently, there has been interest in the use of HDAC inhibitors to activate the expression of mRNAs that are down-regulated in various neurological and psychiatric conditions. Considerably less is known regarding the effect these drugs have on postmitotic cells such as neurons. Before we consider the clinical use of additional HDAC inhibitors to treat schizophrenia or unipolar depression, there are a number of key issues that need to be resolved.

Integrity signals

Registry

Crossref · 10.1124/mol.109.061333

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions
Gottesman, I. I., & Gould, T. D. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.636 · Cited by 5,615
The Role of Chromatin during Transcription
Li, B., Carey, M., & Workman, J. L. (2007) · Cell · doi:10.1016/j.cell.2007.01.015 · Cited by 3,503
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Göttlicher, M., Minucci, S., Zhu, P., Krämer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Coco, F. L., Nervi, C., Pelicci, P. G., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,930
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Histone Deacetylase Is a Direct Target of Valproic Acid, a Potent Anticonvulsant, Mood Stabilizer, and Teratogen
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758
Functions of Site-Specific Histone Acetylation and Deacetylation
Shahbazian, M. D., & Grunstein, M. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.052705.162114 · Cited by 1,635
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast
Pokholok, D., Harbison, C. T., Levine, S. S., Cole, M. F., Hannett, N. M., Lee, T. I., Bell, G. W., Walker, K., Rolfe, A., Herbolsheimer, E., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.026 · Cited by 1,477
Epigenetic regulation in psychiatric disorders
Tsankova, N., Renthal, W., Kumar, A., & Nestler, E. J. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2132 · Cited by 1,400
Cellular Memory and the Histone Code
Turner, B. M. (2002) · Cell · doi:10.1016/s0092-8674(02)01080-2 · Cited by 1,142
Epigenetic mechanisms in memory formation
Levenson, J. M., & Sweatt, J. D. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1604 · Cited by 767
Untitled work
(2002) · PubMed · Cited by 732
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 727
Covalent modifications of histones during development and disease pathogenesis
Bhaumik, S. R., Smith, E. R., & Shilatifard, A. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1337 · Cited by 704
Multiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
Antidepressant Actions of Histone Deacetylase Inhibitors
Covington, H. E., Maze, I., LaPlant, Q. C., Vialou, V. F., Ohnishi, Y. N., Berton, O., Fass, D. M., Renthal, W., Rush, A. J., Wu, E. Y., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1758-09.2009 · Cited by 624
Neurophysiological Endophenotypes of Schizophrenia: The Viability of Selected Candidate Measures
Turetsky, B. I., Calkins, M. E., Light, G. A., D, A. O. M., Radant, A. D., & Swerdlow, N. R. (2006) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl060 · Cited by 575
Histone Deacetylase Inhibitors Exhibit Anti-Inflammatory and Neuroprotective Effects in a Rat Permanent Ischemic Model of Stroke: Multiple Mechanisms of Action
Kim, H. J., Rowe, M. K., Ren, M., Hong, J., Chen, P.-S., & Chuang, D. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120188 · Cited by 560
Antidepressant-Like Effects of the Histone Deacetylase Inhibitor, Sodium Butyrate, in the Mouse
Schroeder, F. A., Lin, C. L., Crusio, W. E., & Akbarian, S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.036 · Cited by 541
Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders
Abel, T. G., & Zukin, R. S. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.12.002 · Cited by 504
Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation
Gurvich, N., Tsygankova, O. M., Meinkoth, J. L., & Klein, P. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0799 · Cited by 470
Epigenetics, DNA Methylation, and Chromatin Modifying Drugs
Szyf, M. (2008) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061008-103102 · Cited by 383
The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons
Yasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., & Chuang, D.-M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002099 · Cited by 358
Clinical Studies of Histone Deacetylase Inhibitors
Prince, H. M., Bishton, M. J., & Harrison, S. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2785 · Cited by 358
Distribution of histone deacetylases 1–11 in the rat brain
Broide, R. S., Redwine, J. M., Aftahi, N., Young, W. G., Bloom, F. E., & Winrow, C. J. (2007) · Journal of Molecular Neuroscience · doi:10.1007/bf02686117 · Cited by 354
The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain
Kim, H. J., Leeds, P., & Chuang, D. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06212.x · Cited by 332
Histone acetyl transferases as emerging drug targets
Dekker, F. J., & Haisma, H. J. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.06.008 · Cited by 322
Anti‐tumor mechanisms of valproate: A novel role for an old drug
Blaheta, R. A., & Cinatl, J. J. (2002) · Medicinal Research Reviews · doi:10.1002/med.10017 · Cited by 274
Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity
Chen, P. S., Wang, C.-C., Bortner, C. D., Peng, G.-S., Wu, X., Pang, H., Lu, R.-B., Gean, P.-W., Chuang, D.-M., & Hong, J.-S. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.06.053 · Cited by 262
Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
Villar‐Garea, A., & Esteller, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20372 · Cited by 247
Targeting histone deacetylase in cancer therapy
Lin, S.-P., Chen, C., Lin, S.-P., Weng, J., & Chen, C. (2006) · Medicinal Research Reviews · doi:10.1002/med.20056 · Cited by 242
Effect of Divalproex Combined with Olanzapine or Risperidone in Patients with an Acute Exacerbation of Schizophrenia
Casey, D. E., Daniel, D. G., Wassef, A. A., Tracy, K. A., Wozniak, P., & Sommerville, K. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300023 · Cited by 232
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Acharya, M. R., Sparreboom, A., Venitz, J., & Figg, W. D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014167 · Cited by 231
The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases
Simonini, M. V., Camargo, L. M., Dong, E., Maloku, E., Veldić, M., Costa, E., & Guidotti, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510341103 · Cited by 230
Isoform-specific histone deacetylase inhibitors: The next step?
Balasubramanian, S., Verner, E. J., & Buggy, J. J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.013 · Cited by 228
Rational Combinations Using HDAC Inhibitors
Bots, M. L., & Johnstone, R. W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2786 · Cited by 218
Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters
Dong, E., Guidotti, A., Grayson, D. R., & Costa, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700529104 · Cited by 194
Epigenetic mechanisms in schizophrenia
Roth, T. L., Lubin, F. D., Sodhi, M., & Kleinman, J. E. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.06.009 · Cited by 176
Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation
Sinn, D.-I., Kim, S.-J., Chu, K., Jung, K., Lee, S., Song, E., Kim, J., Park, D.-K., Lee, S. K., Kim, M., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.02.006 · Cited by 175
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8–mediated apoptosis and down-regulation of c-FLIP protein
Aron, J. L., Parthun, M. R., Marcucci, G., Kitada, S., Mone, A. P., Davis, M. E., Shen, T., Murphy, T. J., Wickham, J., Kanakry, C. G., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3794 · Cited by 171
Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia
Peng, G.-S., Li, G., Tzeng, N., Chen, P.-S., Chuang, D., Hsu, Y., Yang, S., & Hong, J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2004.10.021 · Cited by 169
Relation of serum valproate concentration to response in mania
Bowden, C. L., Janicak, P. G., Orsulak, P. J., Swann, A. C., Davis, J. M., Calabrese, J. R., Goodnick, P. J., Small, J. G., Rush, A. J., Kimmel, S. E., et al. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.6.765 · Cited by 162
HDACi – Targets beyond chromatin
Buchwald, M., Krämer, O. H., & Heinzel, T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.028 · Cited by 160
Histone deacetylases: target enzymes for cancer therapy
Mottet, D., & Castronovo, V. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9131-5 · Cited by 158
MS-275, a potent orally available inhibitor of histone deacetylases—The development of an anticancer agent
Hess‐Stumpp, H., Bracker, T. U., Henderson, D. A., & Politz, O. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.009 · Cited by 156
The Reelin and GAD67 Promoters Are Activated by Epigenetic Drugs That Facilitate the Disruption of Local Repressor Complexes
Kundaković, M., Chen, Y., Guidotti, A., & Grayson, D. R. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.051763 · Cited by 149
Histone deacetylase inhibitors open new doors in cancer therapy
McLaughlin, F., & Thangue, N. B. L. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.034 · Cited by 147
Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition
Hauke, J., Rießland, M., Lunke, S., Eyüpoglu, I. Y., Blümcke, I., El‐Osta, A., Wirth, B., & Hahnen, E. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn357 · Cited by 143
A review of valproate in psychiatric practice
Haddad, P. M., Das, A. K., Ashfaq, M., & Wieck, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902911455 · Cited by 138
HDAC inhibitor-based therapies and haematological malignancy
Stimson, L., Wood, V. H. J., Khan, O. A., Fotheringham, S. A., & Thangue, N. B. L. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn792 · Cited by 136
Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling
Guidotti, A., Dong, E., Kundakovic, M., Satta, R., Grayson, D. R., & Costa, E. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.010 · Cited by 130 · cited 1×
“These drugs also hold promise for therapy relevant to several psychiatric disorders, including schizophrenia, depression, drug addiction, and anxiety disorders (Tsankova et al., 2007; Guidotti et al., 2009).”
BackgroundSelf-citation
The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells
Rießland, M., Brichta, L., Hahnen, E., & Wirth, B. (2006) · Human Genetics · doi:10.1007/s00439-006-0186-1 · Cited by 126
Reversible acetylation of chromatin: Implication in regulation of gene expression, disease and therapeutics
Selvi, R. B., & Kundu, T. K. (2009) · Biotechnology Journal · doi:10.1002/biot.200900032 · Cited by 123
Inhibitors of histone deacetylases as potential therapeutic tools for high‐risk embryonal tumors of the nervous system of childhood
Furchert, S. E., Lanvers‐Kaminsky, C., Juürgens, H., Jung, M., Loidl, A., & Frühwald, M. C. (2007) · International Journal of Cancer · doi:10.1002/ijc.22401 · Cited by 109
Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: Preliminary results from a clinical population
Sharma, R. P., Rosen, C., Kartan, S., Guidotti, A., Costa, E., Grayson, D. R., & Chase, K. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.07.015 · Cited by 109
Randomized, Placebo-Controlled Pilot Study of Divalproex Sodium in the Treatment of Acute Exacerbations of Chronic Schizophrenia
Wassef, A. A., Dott, S. G., Harris, A., Brown, A., O'Boyle, M., Meyer, W. J., & Rose, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00011 · Cited by 98
Therapeutics development for spinal muscular atrophy
Sumner, C. J. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.01.010 · Cited by 97
Biomarkers for predicting clinical responses to HDAC inhibitors
Stimson, L., & Thangue, N. B. L. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.03.016 · Cited by 96
Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population
Gavin, D. P., Kartan, S., Chase, K. A., Jayaraman, S., & Sharma, R. P. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.12.006 · Cited by 92
Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics
Sharma, R. P. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.001 · Cited by 91
Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?
Citrome, L. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.1.55 · Cited by 86
Histone deacetylases: Focus on the nervous system
Morrison, B. E., Majdzadeh, N., & D’Mello, S. R. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7035-9 · Cited by 84
Reviewing the Role of DNA (Cytosine-5) Methyltransferase Overexpression in the Cortical GABAergic Dysfunction Associated with Psychosis Vulnerability
Dong, E., Grayson, D. R., Guidotti, A., Ruzicka, W. B., Veldić, M., & Costa, E. (2007) · Epigenetics · doi:10.4161/epi.2.1.4063 · Cited by 84
The P300 as a possible endophenotype for schizophrenia and bipolar disorder: Evidence from twin and patient studies
Bestelmeyer, P. E. G., Phillips, L. H., Crombie, C., Benson, P., & Clair, D. S. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.035 · Cited by 83
Environmental Studies of Schizophrenia Through the Prism of Epigenetics
Oh, G., & Petronis, A. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn105 · Cited by 76
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275
Eyüpoglu, I. Y., Hahnen, E., Tränkle, C., Savaskan, N. E., Siebzehnrübl, F. A., Buslei, R., Lemke, D., Wick, W., Fahlbusch, R., & Blümcke, I. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0533 · Cited by 71
Reduced baseline acetylated histone 3 levels, and a blunted response to HDAC inhibition in lymphocyte cultures from schizophrenia subjects
Gavin, D. P., Kartan, S., Chase, K. A., Grayson, D. R., & Sharma, R. P. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.04.026 · Cited by 68
Dimethylated lysine 9 of histone 3 is elevated in schizophrenia and exhibits a divergent response to histone deacetylase inhibitors in lymphocyte cultures
Gavin, D. P., Rosen, C., Chase, K. A., Grayson, D. R., Tun, N., & Sharma, R. P. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0932 · Cited by 63
GABAergic promoter hypermethylation as a model to study the neurochemistry of schizophrenia vulnerability
Costa, E., Chen, Y., Dong, E., Grayson, D. R., Kundaković, M., Maloku, E., Ruzicka, W. B., Satta, R., Veldić, M., Zhubi, A., et al. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.9.1.87 · Cited by 62
Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia
Casey, D. E., Daniel, D. G., Tamminga, C. A., Kane, J. M., Tran-Johnson, T. K., Wozniak, P., Abi‐Saab, W., Baker, J. M., Redden, L., Greco, N., et al. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.209 · Cited by 60
Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors
Thomas, E. A. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8067-y · Cited by 54
From trans-methylation to cytosine methylation: Evolution of the methylation hypothesis of schizophrenia
Grayson, D. R., Chen, Y., Dong, E., Kundaković, M., & Guidotti, A. (2009) · Epigenetics · doi:10.4161/epi.4.3.8534 · Cited by 54
Schizophrenia and valproate.
Citrome, L. (2003) · PubMed · Cited by 49
Epigenetic Therapeutic Strategies for the Treatment of Neuropsychiatric Disorders
Deutsch, S. I., Rosse, R. B., Mastropaolo, J. P., Long, K. D., & Gaskins, B. L. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318067e255 · Cited by 42
Divalproex Sodium Augmentation of Haloperidol in Hospitalized Patients With Schizophrenia: Clinical and Economic Implications
Wassef, A. A., Hafiz, N. G., Hampton, D., & Molloy, M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200102000-00006 · Cited by 33
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors
Haefner, M., Blüthner, T., Niederhagen, M., Moebius, C., Wittekind, C., Mössner, J., Caca, K., & Wiedmann, M. W. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3681 · Cited by 30
Creating zinc monkey wrenches in the treatment of epigenetic disorders
Kalin, J. H., Butler, K. V., & Kozikowski, A. P. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.05.007 · Cited by 20

Sorted by citations

Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders
Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“Targeting individual HDAC isoforms is an important aim of drug development (Grayson et al., 2010).”
BackgroundInfluential
Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future
Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 405
HDAC inhibitor‐based therapies: Can we interpret the code?
New, M. I., Olzscha, H., & Thangue, N. B. L. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.003 · Cited by 315
“To act on neurons, it is important for HDIs to cross the bloodebrain barrier, which is the case for valproic acid, SAHA, MS-275, sodium butyrate and phenyl butyrate (Grayson et al., 2010).”
Background
A Role for Repressive Histone Methylation in Cocaine-Induced Vulnerability to Stress
Covington, H. E., Maze, I., Sun, H., Bomze, H. M., DeMaio, K. D., Wu, E. Y., Dietz, D. M., Lobo, M. K., Ghose, S., Mouzon, E., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.007 · Cited by 289
“…postmitotic neurons incorporate changes in transcriptional activity without altering DNA sequence, has received increasing attention for its role in mediating the lasting effects of drugs of abuse and stress on brain function (Borrelli et al., 2008; Grayson et al., 2010; Tsankova et al., 2007).”

See all 172

Authors: Grayson, D. R., Kundakovic, M., & Sharma, R. P.
Affiliations: University of Illinois Chicago (US)
ORCID: Grayson, Dennis R.
Sharma, Rajiv P.
Venue: Molecular Pharmacology
Publisher: Elsevier BV
Published: 2010-02
Volume: 77
Issue: 2
Pages: 126-135
ISSN: 0026-895X (ISSN-L)
DOI: 10.1124/mol.109.061333
OpenAlex: W2099118364
Cited by: 171
References: 85
Citations by year: 2025: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 12 · 2018: 7 · 2017: 9 · 2016: 14 · 2015: 14 · 2014: 22 · 2013: 16 · 2012: 16
FWCI: 1.30
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Molecular Pharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: U.S. Food and Drug Administration
University of Illinois at Chicago
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords: histone deacetylase inhibitors, epigenetic regulation, chromatin biology, histone code, histone acetylation, DNA methylation, mental illness, schizophrenia, major depressive disorder, gene expression, neurons, epigenetic drugs
MeSH terms: Animals, Mental Disorders, Forecasting, Gene Expression Regulation, Histone Deacetylases, Humans, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks